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Abstract
Purpose of review—Pediatric acute kidney injury (AKI) in critically ill patients is associated 
with increased morbidity and mortality. Emerging data support that the incidence of pediatric AKI 
in the ICU is rising. For children with severe AKI, renal replacement therapy (RRT) can provide a 
lifesaving supportive therapy. The optimal timing to deliver and modality by which to deliver RRT 
remain a point of discussion within pediatric (and adult) literature. This review discusses the use 
of RRT for pediatric patients in the ICU. We discuss the most recent evidence-based methods for 
RRT with a focus on continuous RRT.
Recent findings—The feasibility of dialyzing the smallest infants and more medically complex 
children in the ICU is dependent on the advancements in dialysis access and circuit technology. At 
present, data indicate that upward of 27% of children in the ICU develop AKI and 6% require 
RRT. Newer dialysis modalities including prolonged intermittent hemodialysis and continuous 
flow peritoneal dialysis as well as newer dialysis technologies such as the smaller volume circuits 
(e.g., Cardio-Renal Pediatric Dialysis Emergency Machine, Newcastle Infant Dialysis and 
Ultrafiltration System) have made the provision of dialysis safer and more effective for pediatric 
patients of a variety of sizes.
Summary—Renal replacement in the ICU requires a multidisciplinary team approach that is 
facilitated by a pediatric nephrologist in conjunction with intensivists and skilled nursing staff. 
Although mortality rates for children on dialysis remain high, outcomes are improving with the 
support of the multidisciplinary team and dialysis technology advancements.
Keywords
acute kidney injury; pediatric; renal replacement therapy
Correspondence to Lyndsay A. Harshman, MD, Division of Pediatric Nephrology, Stead Family Department of Pediatrics, University 
of Iowa, SE425 General Hospital, 200 Hawkins Drive, Iowa City, IA 52242, USA. Tel: +1 319 356 7249; fax: +1 319 384 9616; 
lyndsay-harshman@uiowa.edu. 
Conflicts of interest
There are no conflicts of interest.
HHS Public Access
Author manuscript
Curr Opin Pediatr. Author manuscript; available in PMC 2020 June 23.
Published in final edited form as:














Acute kidney injury (AKI) is an increasingly frequent health complication, occurring in one 
in three hospitalized children worldwide [1,2]. In a recent prospective study of over 4000 
children admitted to pediatric intensive care units (PICUs) across four continents, AKI 
developed in 26.7% of children of whom 5.8% required renal replacement therapy (RRT) 
[2], with modalities including peritoneal dialysis, hemodialysis, and continuous RRT 
(CRRT). Pediatric AKI is associated with prolonged critical care admissions, greater 
mechanical ventilation needs, and longer overall hospitalizations [3–5]. The incidence of 
chronic kidney disease after pediatric AKI is as high as 20–50% with 10–12% of children 
requiring chronic dialysis within 5 years after hospital discharge [6–8]. Furthermore, the 
presence of AKI is associated with significantly higher mortality in hospitalized children 
with mortality rates as high at 30–50% in children requiring RRT [9,10]. However, it is well 
accepted that effective and appropriately prescribed RRT is associated with significantly 
better survival [11,12].
In this review, we will provide current literature-supported indications for RRT and discuss 
the use of RRT in parallel with the unique technical challenges associated with providing 
RRT in the smallest of children.
INDICATIONS FOR DIALYSIS IN THE ICU
The optimal timing of initiation of RRT for patients remains unknown. RRT is not risk-free, 
and careful consideration to use must be given on an individual basis. Overall, RRT is 
generally safe – even in infants – although it is not without risk for complication such as 
allergic reactions to system components, hypotension, fatal arrhythmias, complications of 
anticoagulation, and complications due to vascular access [13]. There is a strong consensus 
that the benefits of RRT outweigh the risks for universal indications such as life-threatening 
hyperkalemia, acidosis, intoxications/ingestions, hyperammonemia/inborn errors of 
metabolism, severe symptomatic uremia, oliguria/anuria, and volume overload associated 
with AKI. It is also well established that there is no well defined serum creatinine, cystatin 
C, or blood urea nitrogen value in pediatric patients that indicates the need for dialysis; 
however, emerging urinary biomarkers are increasingly being used to predict the need for 
dialysis. For example, urine neutrophil gelatinase-associated lipocalin has been shown to 
accurately detect AKI earlier and predict the need for dialysis in children after cardiac 
surgery better than serum creatinine alone [14]. Finally, several studies have evaluated the 
approach to RRT for sepsis-induced AKI. Cumulatively, there has been no definitive 
advantage shown with initiation of RRT for sepsis-induced AKI alone [11].
Fluid overload
Fluid overload may co-occur with AKI; for example, due to need for aggressive fluid 
resuscitation in septic patients or those with left ventricular cardiac dysfunction. Fluid 
overload is strongly associated with heightened morbidity and mortality in pediatric critical 
care patients; however, the underlying physiology leading to poor outcome is yet to be fully 
delineated [15,16]. Those with overt fluid overload not responsive to diuretics require 
consideration of RRT. Evaluation and team-based discussion for RRT should occur in the 
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setting of more than 10% cumulative fluid overload. Initiation of RRT is advised if 
cumulative fluid overload is more than 20% [17]. Cumulative percentage fluid overload can 
be calculated as follows:
Fluid input in liters − fluid output in liters
ICU admission weight kg × 100
When evaluating daily fluid goals and fluid overload, the multidisciplinary team must ensure 
that adequate nutritional volume can be provided. Inability to provide nutrition due to fluid 
overload should signal strong consideration to early RRT implementation to prevent further 
fluid and electrolyte disturbance.
TECHNICAL CHALLENGES AND CONSIDERATIONS TO PROVIDING RENAL 
REPLACEMENT THERAPY IN THE PEDIATRIC INTENSIVE CARE UNITS
The decision to offer RRT to the smallest pediatric patients is complicated by a multitude of 
challenges that require a multidisciplinary team approach: pediatric patient size and a 
limited availability of appropriately sized dialysis catheters; lack of machines designed for 
neonates and small pediatric patients; and certainly, the technical difficulties associated with 
access placement in the smallest of patients.
Patient size is a primary factor in choosing an RRT modality in the ICU. Size, particularly 
small size, may lead to significant technical challenges with placement of dialysis access. 
Currently available CRRT machines approved for use in the United States are approved by 
the Food and Drug Administration for patients weighing more than 25 kg; however, off-label 
use occurs routinely in pediatric nephrology care for children less than 25 kg given lack of 
otherwise feasible dialytic options. In neonates, peritoneal dialysis is often considered a 
first-line dialytic modality to support critically ill neonates with AKI, oliguria, and fluid 
overload. Peritoneal dialysis has distinct advantages to blood-based methods of RRT in that 
there is no vascular access required, no extracorporeal circuit, and no requirement for 
anticoagulation to provide RRT.
With use of filtration-based modalities, including CRRT and intermittent hemodialysis 
(IHD), it is possible that the circuit extracorporeal circuit volume in neonates and small 
children could be greater than 10–15% of a child’s blood volume. This necessitates the use 
of packed red blood cells to prime the circuit [18]. Blood priming a dialysis circuit increases 
the risk of reactions such as hypotension, hyperkalemia, hypocalcemia, and/or coagulopathy 
at circuit initiation [19]. These reactions are potentiated by both bradykinin release when 
packed red blood cells contact the hemodialysis filter membrane and due to the citrate 
containing preservatives in the blood products. Preparatory maneuvers can be done to 
diminish the bradykinin effect associated with blood priming a circuit such as administration 
of bicarbonate during circuit initiation, buffering the red cells used for blood prime, and/or 
administering the blood cells for blood prime postfilter [20]. Blood priming a circuit also 
sensitizes the immune system to blood antigens, an important concern for patients who may 
be more likely to require kidney transplantation in their future.
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Dialysis access may be technically challenging to obtain for neonates and small children. 
The minimum recommended catheter size for hemodialysis is a 7-French double lumen [21]. 
With consideration given to Poiseuille’s law (resistance to flow through a tube is inversely 
proportional to the fourth power of its radius), the wider and shorter the lumen the higher the 
likelihood of achieving optimal blood flows and successful dialysis [22]. Catheters are 
generally dual lumen and composed of either silicone or polyurethane material. The 
preferred location for catheter placement is the right internal jugular vein. Catheter insertion 
in the right internal jugular vein is associated with a lower risk for complications compared 
with other potential catheter insertion sites [23–25]. Placement of the catheter in the 
subclavian vein increases risk of subclavian stenosis which, in turn, may prevent future 
attempts at creation of an arteriovenous (AV) fistula in the upper extremity [26]. The 
catheter tip should be located at the junction of the superior vena cava and right atrium (RA) 
or in the RA to provide adequate blood flow for RRT.
An additional consideration with vascular catheter placement is the use of a tunneled versus 
non tunneled access. Tunneled vascular catheters have the primary advantage of long-term 
use and feasibility for use at hospital discharge in outpatient dialysis units compared with 
temporary catheters. Temporary catheters carry a higher risk of infections and thrombosis 
and often require replacement due to dysfunction whereas tunneled vascular catheters are 
associated with longer patency and lower infection rates compared with nontunneled 
(temporary) vascular catheters [26,27]. Whereas a temporary catheter can be placed at the 
bedside by the PICU team, tunneled catheters do require more extensive surgery to insert 
and remove, such that nontunneled catheters may be a more appropriate acute option if 
short-term access (<1 week) is anticipated [26]. The ICU and nephrology teams should 
consider the risk for long-term loss of central vascular access with placement of large bore 
catheters and risk for subsequent stenosis of central vessels. The concern may be heightened 
in a patient the primary team believes may someday require long-term RRT in transition to 
organ transplant.
For successful initiation of peritoneal dialysis, the majority of infants and children with AKI 
undergo placement of a double cuffed peritoneal dialysis catheter with a downward or lateral 
positioned exit site that is placed at a distance from any ostomy site and the general diaper 
area to decrease the risk of peritonitis [28]. Successful placement of the peritoneal dialysis 
catheter depends upon an exit site supported by subcutaneous tissue to prevent leakage. 
Whereas infants more than 2–3 kg are candidates for a double cuffed peritoneal dialysis 
catheter, smaller infants less than 2–3 kg often use a single cuffed or acute catheter because 
of their lack of substantial subcutaneous tissue [29]. The thin abdominal wall of low birth 
weight infants can lead to a high incidence of leakage and the need for catheter replacement 
[30,31]. Placement of peritoneal dialysis catheters in infants less than 1 kg may require 
novel positioning and be accompanied by considerable surgical (technical) difficulties 
associated with access placement in extremely low birth weight infants. In infants weighing 
less than 1000 g, case series data report use of single cuff vascular catheters, intravenous 
cannulas, and/or umbilical venous catheters placed in the abdomen as modified peritoneal 
dialysis catheters [32,33]; however, one case report does document use of standard 
peritoneal dialysis equipment in novel positioning for acute peritoneal dialysis in an infant 
weighing less than 1000 g [34] (Fig. 1).
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MODALITIES OF RENAL REPLACEMENT THERAPY COMMONLY USED IN 
THE ICU
The modality chosen to deliver RRT in the pediatric ICU patient is often guided by a variety 
of factors including institutional resources, local expertise, patient characteristics, treatment 
goals, and physician preference.
Continuous renal replacement therapy
CRRT is often the preferred modality for management of the critically ill, hemodynamically 
unstable patient needing dialysis in the ICU [35]. CRRT shares many principles of solute 
clearance and ultrafiltration with IHD but at much lower flow rates [21]. It reduces the risk 
of hypotension and increased intracranial pressure described with IHD via gradual solute 
and fluid removal [21]. Generally, CRRT provides the same solute clearance over 24 h that is 
provided by one IHD session. CRRT provides more efficient clearance than peritoneal 
dialysis with easier to control fluid removal which allows for greater liberalization of fluid 
intake and nutrition [36]. Disadvantages of CRRT primarily relate to the technical 
difficulties with providing therapy to neonates, infants, and small children as most 
commonly available CRRT circuits are not designed for use in persons weighing less than 20 
kg [37]. At present, the most widely used CRRT circuits have extracorporeal volume circuits 
of 80–90 ml or well over 10% of an infant’s blood volume making patients at significantly 
greater risk for hypotension and requiring blood priming of the dialysis tubing and filter as 
described above. However, the Cardio-Renal Pediatric Dialysis Emergency Machine, the 
Newcastle Infant Dialysis and Ultrafiltration System, and the Aquadex show promising 
results as a smaller volume CRRT circuits (20–40 ml) specifically for use in neonates and 
small children and are becoming increasingly available [38▪▪,39,40▪].
CRRT requires careful anticoagulation management to maintain the circuit continuously at 
the slower blood flow rates characteristic of CRRT compared with IHD. Well defined citrate 
and heparin-based anticoagulation protocols have been defined for CRRT [41]. An inherent 
benefit of citrate is that anticoagulation is limited to the circuit rather than systemically 
delivered to the patient. Recent data have also shown longer circuit survival and reduced 
bleeding risks in children receiving citrate anticoagulation compared with heparin 
anticoagulation for CRRT [42–44]. Though of note, citrate anticoagulation protocols may 
need to be adjusted in the setting of liver dysfunction given that citrate is metabolized within 
the liver and can accumulate in liver failure.
In contrast to IHD, CRRT clearance of small solutes is determined by the replacement/
dialysis fluid rate. A standard dose for CRRT is a dialysis fluid rate of 2000 ml/1.73m2/h 
though in the setting of hyperammonemia, high-dose rates of 4000–8000 ml/1.73 m2/h have 
been found to lead to more rapid clearance of ammonia with subsequent reduction in 
dialysate rate (500ml/h or 2000–4000 ml/h/1.73 m2) after consistent fall in ammonia levels 
to less than 400 μmol/l over 12–24 h of therapy [45,46].
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The hemodialysis prescription must be calculated and individualized for each patient to 
provide adequate solute clearance and fluid removal. Assessment and adjustment of the 
prescription is needed prior to each therapy in the PICU setting [47]. Components of the 
hemodialysis prescription include the dialyzer, tubing (i.e., the hemodialysis circuit), blood 
flow rate, dialysate composition, dialysate flow rate, treatment duration and frequency, fluid 
removal goal, and anticoagulation. Similar to CRRT, dialyzer and tubing contain a fixed 
extracorporeal blood volume and should be chosen to maximize solute clearance, yet not 
exceed 10% of the patient’s total blood volume [48].
A hollow-fiber design within the dialyzer is the most common currently in use and contains 
thousands of hollow fibers in parallel structure, similar to the human capillary network. 
Small solute clearance is dependent on the clearance characteristics of the dialyzer, as 
determined by the surface area of the dialyzer [48]. Successful dialysis minimizes blood 
volume retained in the dialyzer but yet provides adequate solute clearance and fluid removal 
across the dialyzer. The tubing chosen provides a circuit from the patient to the dialyzer and 
with a return flow to the patient. Consideration should be given to size of tubing needed 
based on patient age (e.g., infant versus adolescent) [47].
In contrast to CRRT, the blood flow rate for hemodialysis determines the solute clearance: 
higher blood flows increase solute clearance by optimizing diffusion and convection. The 
PICU and nephrology teams must balance the benefits of a higher blood flow to increase 
solute clearance with the potential for cardiovascular compromise at higher blood flow rates.
Dialysate solution typically includes sodium, potassium, calcium, chloride, magnesium, 
bicarbonate, and glucose. Dialysate flow rate, like blood flow rate, is a determinant of solute 
clearance. To maximize the bidirectional transport of small solutes between the blood and 
dialysate, the dialysate flow rate should be at a rate of at least 1.5–2 times the blood flow 
rate [48].
Treatment duration and frequency may vary for the individual patient in the PICU; however, 
daily RRT may be needed in the acute setting. The length of each treatment is determined by 
the amount of solute clearance and fluid removal needed. It should be noted that accurate 
assessment of dry weight in children undergoing acute hemodialysis can be difficult but this 
assessment is essential to reverse the complications of fluid overload including hypertension 
and cardiovascular morbidity [49]. The use of noninvasive monitoring (NIVM) during 
hemodialysis treatments can reduce intradialytic symptoms (e.g., hypotension, headache, 
nausea, vomiting, cramping) while achieving dry weight [50]. NIVM uses hematocrit-guided 
ultrafiltration algorithms for safe and accurate fluid removal. These algorithms allow the 
bedside dialysis nursing staff and physician team to adjust fluid removal goals in real-time 
based on blood volume changes during the hemodialysis treatment. This is particularly 
helpful with younger children who are not able to verbalize symptoms of rapid or excessive 
fluid removal.
Using standard hemodialysis machines, hemodialysis delivered over 6–12h daily with low 
ultrafiltration rates, or prolonged intermittent RRT (PIRRT) has been described in the 
Sanderson and Harshman Page 6













management of pediatric AKI. Survival rates for children with AKI receiving PIRRT have 
been reported as similar to those of children with AKI receiving CRRT (~50%) [51]. PIRRT 
is described as a mechanism to combine the slow sustained modality of continuous 
venovenous hemodialysis, ensuring hemodynamic stability and better biochemical clearance 
along with the cost effectiveness of conventional IHD [52]. Thus, PIRRT maybe particularly 
beneficial in smaller children where there is specific need to reduce the hemodynamic 
instability associated with traditional IHD or the increased clotting and blood loss associated 
with CRRT [53]; however, this modality may be limited in implementation by availability of 
nursing staff in many pediatric centers.
Heparin is the standard anticoagulant used for hemodialysis treatments with unfractionated 
heparin typically given as an initial bolus (25–50 U/kg) followed by a continuous infusion 
during dialysis [48]. In cases of coagulopathy, consideration can be given to use of isotonic 
saline flushes paired without systemic anticoagulation.
Peritoneal dialysis
Peritoneal dialysis is a safe, effective, and inexpensive form of RRT for pediatric AKI. It is 
quite feasible for ages ranging from neonates to adolescents. However, its use has declined 
with the availability of the advancements of extracorporeal therapies described above to 
support smaller infants and children [54]. Advantages of peritoneal dialysis, which are 
especially pertinent for infants and small children, include avoidance of vascular access as a 
critical point for children who are inherently at high-risk for end stage kidney disease and 
potentially in need of vessel preservation for chronic dialysis in the future [55]. 
Hemodynamic instability is infrequent as a result of a more physiologic and less 
proinflammatory process as compared with hemodialysis and in particular is more suitable 
for children who have peritoneal membrane surface areas greater than adults creating a more 
efficient gradient for solute and fluid removal. Peritoneal dialysis is also associated with 
better preservation of residual kidney function compared with hemodialysis. The dialysate 
contains dextrose and can provide a source of supplemental calories for the patient 
undergoing peritoneal dialysis, especially for whom hypoglycemia with fluid restriction may 
be a problem. The typical prescriptions in the setting of AKI involves high volume 
peritoneal dialysis in which each session lasts 24 h and is repeated daily, with a dwell time 
of 30–50 min, dwell volume of 800–1200 ml/m2, and 18–22 exchanges/24h [54]. In addition 
to standard prescriptions, more novel peritoneal dialysis prescriptions can be considered in 
the setting of inadequate clearance or ultrafiltration. Limited data suggest that continuous 
flow peritoneal dialysis (CFPD), using a fixed intraperitoneal volume and continuous flow of 
dialysate into and out of the peritoneal cavity using two peritoneal catheters or one double 
lumen catheter, could be advantageous in hypermetabolic states. To accomplish continuous 
flow, a dialysate flow rate is maintained with fresh peritoneal dialysis solution using an 
adapted CRRT set-up. In a study on the use of CFPD in children with AKI admitted to the 
ICU, CFPD was shown to be nine-fold more effective than conventional peritoneal dialysis 
for ultrafiltration and at least threefold to five-fold more effective for urea and creatinine 
clearance [54,56]. Technical challenges are higher than with standard peritoneal dialysis, 
including variable and unpredictable ultrafiltration rates, risk for infection with two 
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catheters, complex mechanical setup requiring modified CRRT equipment, as well as 
unknown long-term effects of high dialysate flow rate on the peritoneum [57].
Limitations to peritoneal dialysis in the setting of AKI include the potential for mechanical 
obstruction or dysfunction, pericatheter leakage, infection, and hernias secondary to 
increased intraperitoneal pressure [58]. Delayed initiation of peritoneal dialysis for a period 
of 48–72 h or longer after peritoneal dialysis catheter insertion, and use of low fill volumes 
(10 ml/kg) at peritoneal dialysis initiation are most ideal to reduce the risks of these 
complications [3].
MULTIDISCIPLINARY DELIVERY OF RENAL REPLACEMENT THERAPY IN 
THE ICU
Pediatric RRT care is a unique component of critical care and should be provided in a 
pediatric center that is equipped with pediatric dialysis support, including a multidisciplinary 
nursing and physician team from both intensive care and pediatric nephrology specialties to 
deliver appropriate therapy. As noted previously, the equipment for RRT and a patient’s 
individual prescription require modifications across all age and weight populations. The 
multidisciplinary team should review fluid goals, including goals for fluid removal, on a 
daily basis and ensure there is continuous attention to adequacy of dialysis access. Providing 
hemodialysis and CRRT to the smallest patients is an intense and time-consuming process 
that requires attention to detail to ensure patient safety is a top priority. Nursing staff 
providing continuous bedside therapies, such as peritoneal dialysis or CRRT, should receive 
ongoing education to reinforce competency in the modality. AKI in the PICU may also 
require optimization of nutritional status in conjunction with registered dieticians to ensure 
optimal nutrition and metabolic status both during AKI and in renal recovery. Each of these 
unique aspects within the pediatric critical care population must be addressed to provide safe 
and effective RRT.
CONCLUSION
Provision of RRT in the pediatric critical care setting is challenging – our patients may range 
from less than 1kg to nearly 100 kg. There is a dearth of pediatric-specific equipment for 
RRT provision. Delivery of care in a center specializing in pediatric nephrology, with trained 
pediatric dialysis and critical care nurses, benefits the child and family through provision of 
multifaceted resources necessary to facilitate safe and effective provision of RRT.
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• AKI may lead to need for RRT in the setting of metabolic sequelae (e.g., 
hyperkalemia and acidosis) and morbidity and mortality associated with fluid 
overload.
• Filtration-based methods of RRT, such as continuous RRT or hemodialysis, 
may be technically challenging in infants due to lack of pediatric-specific 
machines and difficulty with obtaining adequate vascular access.
• Provision of RRT in the ICU requires interdisciplinary planning between the 
ICU and pediatric nephrology teams as well as trained pediatric nursing staff 
to provide safe and effective RRT.
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Size is a critical limitation for use of dialysis equipment in neonates. An 800-g infant is 
pictured here with use of standard peritoneal dialysis equipment [34]. Note that standard 
equipment was placed in the left upper quadrant to allow for adequate positioning of the 
catheter within the peritoneum.
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